Maternal administration of anti-angiogenic agents, TNP-470 and angiostatin4.5, induces fetal microphthalmia

Molecular Vision

Volumn 15, Issue , 2009, Pages 1260-1269

  Rutland, Catrin S ^a,d   Jiang, Keyi ^b   Soff, Gerald A ^b,e   Mitchell, Christopher A ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ULSTER   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EYE BLOOD FLOW; EYE DEVELOPMENT; FEMALE; FETUS; FETUS DEVELOPMENT; FETUS GROWTH; INTRAUTERINE GROWTH RETARDATION; MALE; MATERNAL TREATMENT; MICROPHTHALMIA; MOTHER FETUS RELATIONSHIP; MOUSE; NONHUMAN; OCULAR BLOOD VESSEL; PLACENTA DEVELOPMENT; PLACENTA DISORDER; PRIORITY JOURNAL; STEREOLOGY;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; CYCLOHEXANES; EYE; FEMALE; FETAL DEVELOPMENT; FETAL DISEASES; FETAL GROWTH RETARDATION; HISTOCYTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICROPHTHALMOS; ORGAN SIZE; PLACENTA; PREGNANCY; RANDOM ALLOCATION; SESQUITERPENES; TERATOGENS;

EID: 67650665286     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. NIH. http://www.cancer.gov/cancertopics/factsheet/Therapy/ angiogenesis-inhibitors. 2007.
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31.
3. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348:555-7.
4. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997; 94:6099-103.
5. Zhang P, Nicholson DE, Bujnicki JM, Su X, Brendle JJ, Ferdig M, Kyle DE, Milhous WK, Chiang PK. Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J Biomed Sci 2002; 9:34-40.
6. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000; 19:97-107.
7. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996; 56:4887-90.
8. Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, Presta M, Albini A, Cassatella MA. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002; 168:5798-804.
9. Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, Mancino A, Sica A, Noonan DM. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med 2009; 7:5.
10. Kang HT, Bang WK, Yu YG. Identification and characterization of a novel angiostatin-binding protein by the display cloning method. J Biochem Mol Biol 2004; 37:159-66.
11. Youn MR, Park MH, Choi CK, Ahn BC, Kim HY, Kang SS, Hong YK, Joe YA, Kim JS, You WK, Lee HS, Chung SI, Chang SI. Direct binding of recombinant plasminogen kringle 1-3 to angiogenin inhibits angiogenin-induced angiogenesis in the chick embryo CAM. Biochem Biophys Res Commun 2006; 343:917-23.
12. Hanford HA, Wong CA, Kassan H, Cundiff DL, Chandel N, Underwood S, Mitchell CA, Soff GA. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res 2003; 63:4275-80.
13. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BK, Wu Z, Gran GE, Shing Y, Soff GA, Bouck N, Pepper MS. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998; 92:4730-41.
14. Sharma MR, Rothman V, Tuszynski GP, Sharma MC. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action. Exp Mol Pathol 2006; 81:136-45.
15. Goretzki L, Lombardo CR, Stallcup WB. Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). J Biol Chem 2000; 275:28625-33.
16. Wajih N, Sane DC. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 2003; 101:1857-63.
17. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001; 152:1247-54.
18. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999; 96:2811-6.
19. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta [3] in endothelial cells. J Biol Chem 2001; 276:39562-8.
20. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 2005; 96:242-61.
21. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 1997; 3:443-6.
22. Rutland CS, Mukhopadhyay M, Underwood S, Clyde N, Mayhew TM, Mitchell CA. Induction of Intrauterine Growth Restriction by Reducing Placental Vascular Growth with the Angioinhibin TNP-470. Biol Reprod 2005; 73:1164-73.
23. Atkinson SD, Rutland CS, Mukhopadhyay M, Yin TT, Loughna P, Soff GA, Mayhew TM, Mitchell CA. Angiostatin is associated with perturbed placental vascular growth and fetal growth restriction (FGR). British Microcirculation Society Meeting; 2007 April 2-3; Belfast (UK).
24. Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 2006; 27:861-8.
25. Rout UK. Valproate, thalidomide and ethyl alcohol alter the migration of HTR-8/SVneo cells. Reprod Biol Endocrinol 2006; 4:44.
26. Hallene KL, Oby E, Lee BJ, Santaguida S, Bassanini S, Cipolla M, Marchi N, Hossain M, Battaglia G, Janigro D. Prenatal exposure to thalidomide, altered vasculogenesis, and CNS malformations. Neuroscience 2006; 142:267-83.
27. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5:423-35.
28. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs 2006; 17:1003-16.
29. Newton HB. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors, Curr Opin Investig Drugs 2007; 8:1009-21.
30. Loeliger M, Briscoe T, Lambert G, Caddy J, Rehn A, Dieni S, Rees S. Chronic placental insufficiency affects retinal development in the guinea pig. Invest Ophthalmol Vis Sci 2004; 45:2361-7.
31. Loeliger M, Duncan J, Loney S, Cock M, Harding I. Rees S. Fetal growth restriction induced by chronic placental insufficiency has long-term effects on the retina but not the optic nerve. Invest Ophthalmol Vis Sci 2005; 46:3300-8.
32. Loeliger M, Louey S, Cock ML, Harding R, Rees SM. Chronic placental insufficiency and fbetal growth restriction lead to long-term effects on postnatal retinal structure. Clin Experiment Ophthalmol 2003; 31:2510-3.
33. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15:4738-47.
34. Alon T, Herno I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-8.
35. Mitchell CA, Rutland CS, Walker M, Nasir M, Foss AJ, Stewart C, Gerhardt K Konerding MA, Risau W, Drexler HC. Unique vascular phenotypes following over-expression of individual VEGFA isoforms from the developing lens. Angiogenesis 2006; 9:209-24.
36. Ash JD, Overbeek PA. Lens-specific VEGF-A expression induces angioblast migration and proliferation and stimulates angiogenic remodeling. Dev Biol 2000; 223:383-98.
37. Ahmed MH, Konno H, Nahar L, Tanaka T, Naito Y, Nakamura S, Baba S. The angiogenesis inhibitor TNP-470 (AGM-1470) improves long-term survival of rats with liver metastasis. J Surg Res 1996; 64:35-41.
38. Koyanagi S, Nakagawa H, Kuramoto Y, Ohdo S, Soeda S, Shimeno H. Optimizing the dosing schedule of TNP-470 [0-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies. J Pharmacol Exp Ther 2003; 304:669-74.
39. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001; 7:977-84.
40. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Suklratme VP, Kufe DW, Weichselbaum RR. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394:287-91.
41. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147:229-63.
42. Mayhew TM, Burton GJ. Methodological problems in placental morphometry: apologia for the use of stereology based on sound sampling practice. Placenta 1988; 9:565-81.
43. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol 2004; 48:1045-58.
44. Rutland CS, Mitchell CA, Nasir M, Konerding MA, Drexler HC. Microphthahnia, persistent layperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF-A188 from the alphaA-crystallin promoter. Mol Vis 2007; 13:47-56.
45. Gervaz P, Fontolliet C. Therapeutic potential of the anti-angiogenesis drug TNP-470. Int J Exp Pathol 1998; 79:359-62.
46. Golzio C, Martinovic-Bouriel J, Thomas S, Mougou-Zrelli S, Grattagliano-Bessieres B, Bonniere M, Delahaye S, Munnich A, Encha-Razavi F, Lyonnet S, Vekemans M, Attie-Bitach T, Etchevers HC. Matthew-Wood syndrome is caused by truncating mutations in the retinol-binding protein receptor gene STRA6. Am J Hum Genet 2007; 80:1179-87.
47. Wong JC, Alon N, McKerlie C, Huang JR, Meyn MS, Buchwald M. Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Hum Mol Genet 2003; 12:2063-76.
48. Male A, Davies A, Bergbaum A. Keeling J, FitzPatrick D, Mackie Ogilvie C, Berg J. Delineation of an estimated 6.7 MB candidate interval for an anophthahnia gene at 3q26.33-q28 and description of the syndrome associated with visible chromosome deletions of this region. Eur J Hum Genet 2002; 10:807-12.
49. Cain CC, Saul D, Attanasio L, Oehler E, Hamosh A, Blakemore K, Stetten G. Microphthalmia with linear skin defects (MLS) syndrome evaluated by prenatal karyotyping, FISH and array comparative genomic hybridization. Prenat Diagn 2007; 27:373-9.
50. Leung CC. Antiserum to rat visceral yolk sac endoderm induced abnormal embryonic development. Pediatr Res 1983; 17:313-8.
51. Hande MP, VeenaK. Teratogenic effect of hyperthermia during early organogepesis period in mice. Teratog Carcinog Mutagen 1993; 13:145-50.
52. Hinzpeter EN, Renz S, Loser H. Eye manifestations of fetal alcohol syndrome. Klin Monatsbl Augenheilkd 1992; 200:33-8.
53. Stromland K. Ocular abnormalities in the fetal alcohol syndrome. Acta Ophthalmol Suppl 1985; 171:1-50.
54. Chan T, Bowell R, O'Keefe M, Lanigan B. Ocular manifestations in fetal alcohol syndrome. Br J Ophthalmol 1991; 75:524-6.
55. Pinazo-Duran MD, Renau-Piqueras J, Guerri C. Developmental changes in the optic nerve related to ethanol consumption in pregnant rats: analysis of the ethanol-exposed optic nerve. Teratology 1993; 48:305-22.
56. Pinazo-Duran MD, Renau-Piqueras J, Guerri C, Stromland K. Optic nerve hypoplasia in fetal alcohol syndrome: an update. Eur J Ophthalmol 1997; 7:262-70.
57. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, O'Reilly M, Folkman J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motifRGD. Proc Natl Acad Sci USA 1998; 95:5579-83.
58. Cook CS, Nowotny AZ, Sulik KK. Fetal alcohol syndrome. Eye malformations in a mouse model. Arch Ophthalmol 1987; 105:1576-81.
59. Cook CS, Sulik KK. Keratolenticular dysgenesis (Peters' anomaly) as a result of acute embryonic insult during gastrulation. J Pediatr Ophthalmol Strabismus 1988; 25:60-6.
60. el-Hifnawi E, el-Hifnawi A, Frankenberg C, Keeler C. Ultrastructure and regression of the tunica vasculosa lentis in newborn Wistar rats. Ann Anat 1994; 176:143-9.
61. Zhang W, Ito Y, Berlin E, Roberts R, Luan H, Berkowitz BA. Specificity of subnormal deltaPO2 for retinal neovascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003; 44:3551-5.
62. Goldberg MF. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am J Ophthalmol 1997; 124:587-626.
63. Hittner HM, Hirsch NJ, Rudolph AJ, Assessment of gestational age by examination of the anterior vascular capsule of the lens. J Pediatr 1977; 91:455-8.
64. Hittner HM, Gorman WA, Rudolph AJ. Examination of the anterior vascular capsule of the lens: II. Assessment of gestational age in infants small for gestational age. J Pediatr Ophthalmol Strabismus 1981; 18:52-4.
65. Hittner HM, Speer ME, Rudolph AJ. Examination of the anterior vascular capsule of the lens: III. Abnormalities in infants with congenital infection. J Pediatr Ophthalmol Strabismus 1981; 18:55-60.
66. Skapinker R, Rothberg AD. Postnatal regression of the tunica vasculosa lentis. J Perinatol 1987; 7:279-81.
67. Renz BE, Vygantas CM. Hyaloid vascular remnants in human neonates. Ann Ophthalmol 1977; 9:179-84.
68. Joussen AM, Beecken WD, Moromizato Y, Schwartz A, Kirchhof B, Poulaki V. Inhibition of inflammatory corneal angiogenesis by TNP-470. Invest Ophthalmol Vis Sci 2001; 42:2510-6.
69. Cretton-Scoft E, Placidi L, McClure H, Anderson DC, Sommadossi JP. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother Pharmacol 1996; 38:117-22.
70. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betshotlz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161:1163-77.
71. Gogat K, Le Gat L, Van Den Berghe L, Marchant D, Kobetz A, Gadin S, Gasser B, Quere I, Abitbol M, Menasche M. VEGF and KDR gene expression during human embryonic and fetal eye development. Invest Ophthalmol Vis Sci 2004; 45:7-14.
72. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D, Folkman J. Inhibition of vessel permeability by TNP-470 and its polymer conjugate caplostatin. Cancer Cell 2005; 7:251-61.
73. Wang YQ, Luk JM, Chu AC, Ikeda K, Man K, Kaneda K, Fan ST. TNP-470 blockage of VEGF synthesis is dependent on MAPK/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells. Biochem Biophys Res Commun 2006; 341:239-44.
74. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T. TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro. Anticancer Res 2000; 20:601-4.
75. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004; 66:1677-85.
76. Yang H, Xu Z, Iuvone PM, Grossniklaus HE. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 2006; 12:511-7.
77. De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 2005; 102.7589-94.
78. Sima J, Zhang SX, Shao C, Fant J, Ma JX. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 2004; 564:19-23.
79. Drixler TA, Borel Rinkes IH, Ritchie ED, Treffers FW, van Vroonhoven TJ, Gebbink MF, Voest EE. Angiostatin inhibits pathological but not physiological retinal angiogenesis. Invest Ophthalmol Vis Sci 2001; 42:3325-30.
80. te Velde EA, Kusters B, Maass C, de Waal R, Borel Rinkes IH. Histological analysis of defective colonic healing as a result of angiostatin treatment. Exp Mol Pathol 2003; 75:119-23.
81. Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 2002; 105:2185-91.
82. Parentin F, Tonini G, Perissutti P. Refractive evaluation in children with growth defect. Curr Eye Res 2004; 28:11-5.
83. Hellstrom A, Hard AL, Svensson E, Niklasson A. Ocular fundus abnormalities in children born before 29 weeks of gestation: a population-based study. Eye 2000; 14:324-9.
84. Hellstrom A, Svensson E, Carlsson B, Niklasson A, Albertsson-Wikland K. Reduced retinal vascularization in children with growth hormone deficiency. J Clin Endocrinol Metab 1999; 84:795-8.
85. Hellstrom A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, Savage M. svensson E, Smith L, Weinberger D, Albertsson Wikland K, Laron Z. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002; 87:3413,6.
86. Igarashi T, Miyake K, Kato K, Watanabe A, Ishizaki M, Ohara K, Shimada T. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther 2003; 10:219-26.
87. Sima J, Ma J, Zhang SX, Guo J. Study of the influence of angiostatin intravitreal injection on vascular leakage in retina and iris of the experimental diabetic rats. Yan Ke Xue Bao 2006; 22:252-8.
88. Klein SA, Bond SJ, Gupta SC, Yacoub OA, Anderson GL. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 1999; 82:268-74.